[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"gestational-diabetes\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:gestational-diabetes":31},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,59,0,25,[9,46,73,97,118,139,166,196,224,260,283,308,345,367,393,424,464,486,512,536,562,592,614,641,663],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100578685","delivering-hope-helping-women-optimize-prenatal-equity-100578685",false,"NCT06814509","Delivering HOPE (Helping Women Optimize Prenatal Equity)","Inclusion Criteria:\n\n* Aged 16-44 years\n* ≤18 weeks pregnant\n* Speak English, Spanish, or Marshallese\n* Valid email address",true,"FEMALE","16 Years","44 Years",{"count":21,"type":22},1440,"ESTIMATED","INTERVENTIONAL",[25],"NA","The overarching research question is: \"Does the provision of healthy food (Delivering HOPE) during pregnancy reduce the proportion of women who experience excessive gestational weight gain compared with enhanced standard of care (ESoC)?\" To answer this question, the investigators will conduct a large multi-site randomized controlled trial with 1,440 women. Women will be randomized to either the Delivering HOPE arm or the ESoC arm, with approximately 720 participants per arm. Participants randomized to the ESoC arm will receive the standard clinical protocol for nutritional and gestational weight gain counseling recommended for all pregnant women, WIC and SNAP enrollment assistance, referrals to safety net food organizations.Those randomized to the Delivering HOPE arm will be provided the same nutritional and gestational weight gain counseling, WIC and SNAP assistance, and food referrals, as well as a total of $1000\u002F$2000\u002F$3000 (depending on household size) during pregnancy to be used specifically for the purchase of healthy foods recommended in the nutritional counseling. Data for the primary outcome (pre-pregnancy weight and weight at delivery) will be collected from birth records.",[28,29,30,31,32],"Gestational Weight Gain","Diet, Healthy","Gestational Hypertension","Gestational Diabetes","Pregnancy Complications","RECRUITING","2026-06-25",{"date":36,"type":37},"2026-06-26","ACTUAL",{"date":39,"type":37},"2025-06-24",{"date":41,"type":22},"2029-12-31",{"name":43,"class":44},"University of Arkansas","OTHER",8,{"id":47,"slug":48,"hasResults":12,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":52,"eligibilityCriteria":53,"healthyVolunteers":12,"sex":17,"minAge":54,"maxAge":55,"enrollmentInfo":56,"targetDuration":4,"studyType":23,"phases":58,"briefSummary":59,"conditions":60,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":72},"100448849","intensive-glycemic-targets-in-overweight-and-obese-women-with-gestational-diabetes-100448849","NCT05124808","Intensive Glycemic Targets in Overweight and Obese Women With Gestational Diabetes","Intensive Glycemic Targets in Overweight and Obese Women With Gestational Diabetes Mellitus: A Multicenter Randomized Trial","iGDM","Inclusion Criteria:\n\n* Pregnant women between the ages of 18-45\n* Singleton gestation\n* Gestational age between 12 0\u002F7-32 6\u002F7 weeks' gestation with gestational diabetes diagnosed during this time frame using either a 50g 1-hr GCT ≥200 mg\u002FdL or two or more abnormal values on a 100g OGTT using the Carpenter-Coustan Criteria\n* Overweight or obese BMI at the first prenatal visit (BMI ≥25 kg\u002Fm2 or ≥23 kg\u002Fm2 in Asian Americans)\n\nExclusion Criteria:\n\n* Inability or unwillingness to provide informed consent\n* Inability to communicate with members of the study team, despite the presence of an interpreter\n* Planned delivery at a non-study affiliated hospital\n* Known renal disease with a baseline creatinine \\>1.5 mg\u002FdL\n* Significant fetal anomalies diagnosed prior to study enrollment (these will include anomalies such as gastroschisis, spina bifida, complex congenital heart disease, or serious karyotypic anomalies that may lead to early delivery or increased risk of neonatal death)\n* Oral or IV\u002FIM steroid use within 7 days of study enrollment","18 Years","45 Years",{"count":57,"type":22},828,[25],"This is a multicenter randomized clinical trial of 828 overweight and obese individuals with gestational diabetes designed to compare standard to intensive glycemic targets.",[31,61,62],"Pregnancy, High Risk","Overweight and Obesity","2026-06-22",{"date":65,"type":37},"2026-06-24",{"date":67,"type":37},"2022-03-01",{"date":69,"type":22},"2026-12-31",{"name":71,"class":44},"Indiana University",5,{"id":74,"slug":75,"hasResults":12,"nctId":76,"briefTitle":77,"officialTitle":78,"acronym":4,"eligibilityCriteria":79,"healthyVolunteers":12,"sex":17,"minAge":54,"maxAge":4,"enrollmentInfo":80,"targetDuration":4,"studyType":23,"phases":82,"briefSummary":83,"conditions":84,"keywords":86,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":89,"startDateStruct":90,"completionDateStruct":92,"leadSponsor":94,"locationsCount":96},"100551211","preventing-t2dm-after-gdm-with-immediate-postpartum-screening-100551211","NCT06457139","Preventing T2DM After GDM With Immediate Postpartum Screening","Preventing Type 2 Diabetes Mellitus After Gestational Diabetes Mellitus With Immediate Postpartum Screening","Inclusion Criteria:\n\n* pregnancy complicated by GDM as diagnosed with traditional two step testing in the third trimester according to Carpenter-Coustan Criteria\n* receiving prenatal care at UMASS Memorial and plans to deliver at UMASS Memorial\n* able and willing to provide informed consent\n* ability to complete immediate in hospital postpartum glucose testing\n* have evidence of impaired glucose metabolism defined as fasting glucose value of ≥126 mg\u002FdL or 2-hour glucose value of ≥200 mg\u002FdL\n\nExclusion Criteria:\n\n* known diagnosis of pre-existing pre-gestational diabetes in pregnancy\n* inability to complete oral glucose tolerance test (e.g. gastric bypass surgery history, gastric dumping syndrome history, vomiting of oral glucose tolerance test) in pregnancy or immediately postpartum\n* systemic steroid use",{"count":81,"type":22},116,[25],"The overall goal of this proposal is to create and test an implementation protocol for in-hospital immediate postpartum diabetes screening for postpartum patients with pregnancies affected by GDM.",[31,85],"Type 2 Diabetes",[87],"diabetes","2026-06-19",{"date":65,"type":37},{"date":91,"type":37},"2025-06-01",{"date":93,"type":22},"2027-12-01",{"name":95,"class":44},"University of Massachusetts, Worcester",1,{"id":98,"slug":99,"hasResults":12,"nctId":100,"briefTitle":101,"officialTitle":101,"acronym":4,"eligibilityCriteria":102,"healthyVolunteers":12,"sex":17,"minAge":54,"maxAge":55,"enrollmentInfo":103,"targetDuration":4,"studyType":23,"phases":105,"briefSummary":106,"conditions":107,"keywords":4,"overallStatus":108,"whyStopped":4,"lastUpdateSubmitDate":109,"lastUpdatePostDateStruct":110,"startDateStruct":112,"completionDateStruct":114,"leadSponsor":116,"locationsCount":96},"100642983","therapeutic-synergy-of-probiotic-augmented-conventional-antidiabetic-pharmacotherapy-in-gestational-diabetes-mellitus-100642983","NCT07645001","Therapeutic Synergy of Probiotic Augmented Conventional Antidiabetic Pharmacotherapy in Gestational Diabetes Mellitus","Inclusion Criteria:\n\n* Pregnant women (18-45 years of age).\n* Diagnosed with GDM between 18-26 weeks of gestation.\n* Singleton pregnancy. (Multiple gestations carry inherently higher risks like preterm birth, growth restriction and neonatal morbidity, Inclusion may introduce confounding thus restricting singleton pregnancies ensures population homogeneity).\n\nExclusion Criteria:\n\n* Pre-existing diabetes mellitus.\n* Pregnancy induced hypertension.\n* Chronic gastrointestinal, hepatic, or renal disease.\n* Use of antibiotics or probiotics within the previous 4 weeks.\n* Multiple pregnancy.\n* Pregnancy with known fetal anomalies.",{"count":104,"type":22},200,[25],"1. To compare the effects of metformin, insulin, and their combination with multistrain probiotics on glycemic control and insulin resistance in women with gestational diabetes mellitus (GDM), assessed by FPG, HbA1c, fasting insulin, and HOMA-IR.\n2. To compare the effects of metformin, insulin, and their combination with multistrain probiotics on inflammatory biomarkers in women with GDM.\n3. To determine the effect of multistrain probiotic supplementation alongside standard therapy on maternal and neonatal outcomes, including gestational age at delivery, mode of delivery, birth weight, Apgar score, and NICU admission.",[31],"NOT_YET_RECRUITING","2026-06-08",{"date":111,"type":37},"2026-06-12",{"date":113,"type":22},"2026-07",{"date":115,"type":22},"2027-06",{"name":117,"class":44},"Riphah International University",{"id":119,"slug":120,"hasResults":12,"nctId":121,"briefTitle":122,"officialTitle":122,"acronym":4,"eligibilityCriteria":123,"healthyVolunteers":12,"sex":17,"minAge":54,"maxAge":4,"enrollmentInfo":124,"targetDuration":4,"studyType":23,"phases":126,"briefSummary":127,"conditions":128,"keywords":129,"overallStatus":108,"whyStopped":4,"lastUpdateSubmitDate":109,"lastUpdatePostDateStruct":131,"startDateStruct":133,"completionDateStruct":135,"leadSponsor":137,"locationsCount":4},"100595577","continuous-glucose-monitoring-to-detect-postpartum-dysglycemia-in-patients-with-gestational-diabetes-100595577","NCT07034261","Continuous Glucose Monitoring to Detect Postpartum Dysglycemia in Patients With Gestational Diabetes","Inclusion Criteria:\n\n1. Age greater than or equal to 18\n2. Completed pregnancy with delivery of a live born infant(s). Pregnancies with multiple gestations will be included\n3. No prior history of type 1 or type 2 diabetes\n\n   \\* Patients with a history of gestational diabetes (GDM) in a prior pregnancy will be eligible for inclusion.\n4. GDM diagnosis by standard screening at 24-28 weeks\n\n   * 2 hour 75g oral glucose tolerance test (OGTT); one abnormal value required for diagnosis\n\n     * Fasting glucose 92\n     * 1 hour 180\n     * 2 hour 153\n   * 3 hour 100g OGTT - two abnormal values required for diagnosis\n\n     * Fasting glucose - 95\n     * 1 hour 180\n     * 2 hour 155\n     * 3 hour 140\n\nThere are no exclusion criteria for this study. Eligibility will be based on inclusion criteria.",{"count":125,"type":22},50,[25],"The aim of this study is to determine the ability of postpartum continuous glucose monitoring (CGM) for subjects with gestational diabetes (GDM) to predict dysglycemia on 4-12 week postpartum oral glucose tolerance test (OGTT).",[31],[130],"CGM Device",{"date":132,"type":37},"2026-06-11",{"date":134,"type":22},"2026-09",{"date":136,"type":22},"2027-09",{"name":138,"class":44},"University of Chicago",{"id":140,"slug":141,"hasResults":12,"nctId":142,"briefTitle":143,"officialTitle":144,"acronym":145,"eligibilityCriteria":146,"healthyVolunteers":12,"sex":17,"minAge":54,"maxAge":4,"enrollmentInfo":147,"targetDuration":4,"studyType":23,"phases":149,"briefSummary":150,"conditions":151,"keywords":152,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":156,"lastUpdatePostDateStruct":157,"startDateStruct":159,"completionDateStruct":161,"leadSponsor":163,"locationsCount":165},"100539939","continuous-glucose-monitoring-for-women-with-gestational-diabetes-100539939","NCT06310356","Continuous Glucose Monitoring for Women With Gestational Diabetes","Continuous Glucose Monitoring for Women With Gestational Diabetes: a Randomized Controlled Trial","CORDELIA","Inclusion Criteria:\n\n* At least 18 years of age at the time of signing the Informed Consent Form (ICF)\n* Singleton pregnancy\n* Diagnosed with gestational diabetes before 29.6 weeks of pregnancy\n* Needs to be able to understand and speak Dutch, French or English.\n* Have email access\n\nExclusion Criteria:\n\n* Patient has a history of type 2 or type 1 diabetes, or presence of auto-immune antibodies for type 1 diabetes\n* A physical or psychological disease likely to interfere with the conduct of the study (based on the evaluation by the treating physician).\n* Use of medication with significant impact on glycemia (such as high dose glucocorticoids and diabetes medication such as metformin)\n* Participation in an interventional Trial with an investigational medicinal product or device\n* Multiple pregnancy\n* History of bariatric surgery\n* Known allergy to the adhesives used with the continuous glucose monitoring",{"count":148,"type":22},386,[25],"There are a few ongoing large randomized controlled trials (RCT's) on continuous glucose monitoring (CGM) in women with gestational diabetes (GDM) powered for pregnancy outcomes. However, none of these studies included women diagnosed with early GDM. The CORDELIA trial is a Belgian-Australian open-label multi-centric RCT with 16 centers in women with GDM (including both early and late GDM). Women will be randomized 1\u002F1 to either treatment with CGM (intervention group, Freestyle Libre 3 +) or continue with self-monitoring of blood glucose (SMBG) with glucometer in line with normal routine (control arm). The study ends at the postpartum oral glucose tolerance test (OGTT 6-24 weeks postpartum) to screen for glucose intolerance.",[31],[153,154,155],"gestational diabetes","continuous glucose monitoring","early gestational diabetes","2026-06-05",{"date":158,"type":37},"2026-06-09",{"date":160,"type":37},"2024-11-18",{"date":162,"type":22},"2027-08",{"name":164,"class":44},"Universitaire Ziekenhuizen KU Leuven",16,{"id":167,"slug":168,"hasResults":12,"nctId":169,"briefTitle":170,"officialTitle":171,"acronym":172,"eligibilityCriteria":173,"healthyVolunteers":12,"sex":17,"minAge":54,"maxAge":4,"enrollmentInfo":174,"targetDuration":4,"studyType":23,"phases":176,"briefSummary":177,"conditions":178,"keywords":180,"overallStatus":108,"whyStopped":4,"lastUpdateSubmitDate":188,"lastUpdatePostDateStruct":189,"startDateStruct":190,"completionDateStruct":192,"leadSponsor":194,"locationsCount":4},"100611692","mobile-based-obstetric-monitoring-for-pregnancies-complicated-by-hypertension-andor-diabetes-mom-hd-100611692","NCT07243886","Mobile-based Obstetric Monitoring for Pregnancies Complicated by Hypertension and\u002For Diabetes (MOM-HD)","Mobile-based Obstetric Monitoring for Pregnancies Complicated by Hypertension and\u002For Diabetes (MOM-HD): a Type II Hybrid Implementation-Effectiveness Trial","MOM-HD","Inclusion Criteria:\n\n* Pregnant women receiving antenatal care at RCT site\n* Diagnosed with one of the following:\n\n  * Chronic hypertension (sustained systolic BP ≥140 mm Hg and\u002For diastolic BP ≥90 mm Hg, or on antihypertensive treatment before 20 weeks of gestation)\n  * Gestational hypertension or preeclampsia without severe features (sustained systolic BP ≥140 mm Hg and\u002For diastolic BP ≥90 mm Hg after 20 weeks of gestation)\n  * Gestational diabetes\n* Age 18 years or older\n* Access to a smartphone\n* Gestational age ≤ 34 weeks at enrollment\n\nExclusion Criteria:\n\n* Multifetal pregnancies\n* Apparent communication difficulties (e.g., hearing, speech, or cognitive impairments), as judged by research assistants\n* Unable to understand the Nepali language\n* Severe maternal illness or any condition that precludes active study participation (e.g., preeclampsia with severe features, eclampsia, HELLP syndrome, or other conditions requiring inpatient management)\n* Declines to provide informed consent",{"count":175,"type":22},864,[25],"Hypertensive disorders during pregnancy (HDP) and gestational diabetes (GDM) are among the leading complications in pregnancy, significantly contributing to global maternal and fetal morbidity and mortality. (1,2,3) Effective management of HDP and GDM hinges on regular monitoring of blood pressure (BP) and blood glucose (BG) to ensure adequate control and timely interventions for maternal and fetal well-being. Telemonitoring offers a promising and cost-effective alternative by enabling pregnant individuals to monitor BP and BG at home and share real-time results with healthcare providers, facilitating informed clinical decision-making and timely interventions.\n\nHere the investigators propose to conduct a Hybrid Type II Effectiveness-Implementation Randomized Controlled Trial (RCT) to assess the effectiveness and evaluate the implementation of the MOM-HD (Mobile-based Obstetric Monitoring for Hypertension and\u002For Diabetes) program, a mobile app-based perinatal telemonitoring program, in real-world clinical settings in Nepal. To address the study aims, the investigators will recruit 864 women who are newly diagnosed with HDP and GDM from three metropolitan hospitals and randomly assign them to either (i) MOM-HD + standard care or (ii) standard care alone, from enrolment in pregnancy to 6 weeks postpartum. Primary and secondary clinical outcomes will be assessed at delivery, and at 6 weeks postpartum. The investigators hypothesize that compared to standard care, the use of MOM-HD in addition to standard care will result in lower systolic BP levels, lower incidence rate for the composite adverse perinatal outcome of either perinatal loss, neonatal intensive care unit admission, primary cesarean delivery or labor induction, and lower proportion of days with elevated systolic BP or BG readings between recruitment and 6 weeks postpartum. A convergent mixed-methods approach will be used to assess implementation and maintenance outcomes using the RE-AIM framework (4), and economic sustainability will be assessed by collecting primary cost data.",[31,179],"Hypertensive Disorder of Pregnancy",[181,182,183,184,185,186,187],"pregnancy","telemonitoring","mHealth","GDM","HDP","Nepal","implementation","2026-06-03",{"date":156,"type":37},{"date":191,"type":22},"2026-09-01",{"date":193,"type":22},"2030-12-31",{"name":195,"class":44},"Rutgers, The State University of New Jersey",{"id":197,"slug":198,"hasResults":12,"nctId":199,"briefTitle":200,"officialTitle":201,"acronym":202,"eligibilityCriteria":203,"healthyVolunteers":12,"sex":17,"minAge":54,"maxAge":4,"enrollmentInfo":204,"targetDuration":4,"studyType":23,"phases":206,"briefSummary":207,"conditions":208,"keywords":209,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":214,"lastUpdatePostDateStruct":215,"startDateStruct":217,"completionDateStruct":219,"leadSponsor":221,"locationsCount":223},"100397191","early-gestational-diabetes-mellitus-100397191","NCT04451915","Early Gestational Diabetes Mellitus","Late Versus Early Management of Gestational Diabetes Mellitus: a Non Inferiority Randomized Multicenter Trial","LEMA_GDM","Inclusion Criteria:\n\n* Pregnant woman\n* Singleton pregnancy\n* Early GDM defined by a fasting plasma glucose between 5.1 mmol\u002Fl and 6.1 mmol\u002F with at least one risk factor (age ≥35 years and\u002For BMI ≥ 25 kg\u002Fm2 and\u002For familial history of diabetes and\u002For personal history of GDM and\u002For personal history of macrosomia).\n* First prenatal visit prior 20 weeks of gestation at the time of randomization.\n* Signed informed consent\n\nExclusion Criteria:\n\nDiabetic follow-up started at time of inclusion\n\n* Pre-existing diabetes in pregnancy\n* Renal impairment\n* Hepatic insufficiency\n* History of bariatric surgery\n* Long time corticosteroids treatment\n* Insufficient understanding\n* Language difficulties\n* Lack of social Insurance\n* Person in emergency situation\n* Person under the protection of justice (tutelage\u002F curatorship)\n* Persons deprived of their liberty",{"count":205,"type":22},2010,[25],"In 2010, the International Association of the Diabetes and Pregnancy Study Groups (IADPSG) panel published consensus-based recommendations on the diagnosis and classification of hyperglycemia in pregnancy. Cognizant that milder degrees of hyperglycemia would also be detected by early pregnancy testing, the IADPSG recommended that fasting plasma glucose (FPG) in the range of 5.1-6.9 mmol\u002Fl should be considered diagnostic of early Gestational Diabetes Mellitus (GDM) even if the level of proof for this recommendation is very low regarding to prognosis. This threshold was extrapolated from the FPG value used between 24 and 28 weeks.\n\nIn France, a FPG is proposed at the first prenatal visit for women with risk factors of GDM. Early GDM is diagnosed if FPG is ≥ 5.1 mmol\u002Fl, leading to an intensive metabolic management. Data have shown that GDM prevalence increased rapidly from 5.9% in 2009 to 9.3% in 2014. 26.9% of women with hyperglycemia during their pregnancy but without known diabetes are treated before 22 weeks' gestation (WG). More recent data from Italy and China, where IADPSG diagnosis criteria were applied, have strongly challenged this recommendation, and showed that early FPG ≥ 5.1mmo\u002FL is poorly predictive of later GDM. No prior studies have demonstrated benefits to early screening and management. In 2016, the IADPSG members have suggested that the use of the FPG threshold ≥5.1 mmol\u002Fl for the identification of GDM in early pregnancy is not justified by current evidence",[31],[210,181,211,212,213],"Early gestational diabetes","fasting plasma glucose","diagnosis","prognosis","2026-05-28",{"date":216,"type":37},"2026-06-02",{"date":218,"type":37},"2020-11-30",{"date":220,"type":22},"2027-06-30",{"name":222,"class":44},"University Hospital, Lille",10,{"id":225,"slug":226,"hasResults":12,"nctId":227,"briefTitle":228,"officialTitle":229,"acronym":4,"eligibilityCriteria":230,"healthyVolunteers":12,"sex":231,"minAge":54,"maxAge":4,"enrollmentInfo":232,"targetDuration":234,"studyType":235,"phases":4,"briefSummary":236,"conditions":237,"keywords":242,"overallStatus":108,"whyStopped":4,"lastUpdateSubmitDate":250,"lastUpdatePostDateStruct":251,"startDateStruct":253,"completionDateStruct":255,"leadSponsor":257,"locationsCount":4},"100637631","cgm-experience-preferences--blood-glucose-parameters-100637631","NCT07607015","CGM Experience, Preferences & Blood Glucose Parameters","Instara™-1 Dual Perspectives on Continuous Glucose Monitoring: Understanding Patient Experience and Healthcare Professional Preferences","Inclusion Criteria:\n\n* Subjects to provide written informed consent prior to any study procedures being performed\n* Subjects with age 18 and above both male and female\n* Diagnosed with Diabetes Miletus Type I, Type II and\u002For GDM\n* Comfortable using smart phone, access to internet along with Bluetooth connectivity throughout the study duration.\n* Subjects (Patients) on oral or injectable anti-diabetic medications, (in case of insulin, patient must be on insulin from last 3 months )\n* Subjects (HCPs) healthy, Pre-diabetes or Diabetes Miletus (any type)\n\nExclusion Criteria:\n\n* History of hypersensitivity to any of the active or inactive ingredients of the CGM device used in the trial, and\u002For history of significant allergic skin reactions.\n* Presence of severe diabetes complications e.g. retinopathy, acute metabolic crisis, etc.\n* History of active\u002F acute renal and\u002For hepatic failure.\n* Patients who have been admitted to the hospital in the past 3 months for diabetic ketoacidosis (DKA) and hyperosmolar hyperglycemic state.\n* History of critical illness or incapacitated patients\n* History of acute psychiatric disorder or exacerbation of chronic psychiatric disorder.\n* History or presence of a medical condition or disease that in the investigator's opinion would embarrass glycemic control and completion of the study.\n* Medical conditions that require patients to undergo frequent radiation\u002F imaging procedures for example CT, MRI and X rays\n* History of known hematological disorders such as Sickle Cell Disease \\& Trait, Thalassemia, Hemolytic Anemias (e.g., G6PD deficiency, autoimmune), Iron Deficiency Anemia\n* Patients on high doses of acetaminophen (\\>1 gram every 6 hours), ascorbic acid supplements (e.g., \\> 500-1000 mg\u002Fday), IV sorbitol, steroids and aspirin which can alter the readings on the CGM device.","ALL",{"count":233,"type":22},75,"3 Months","OBSERVATIONAL","This is an open-label, prospective, multicenter observational study designed to evaluate the perceived benefits, device experience, preference, and glucose-related parameters associated with the Instara-1 Continuous Glucose Monitoring device. The study will include patients with diabetes and healthcare professionals. Patients will use Instara- 1 and will be followed up to assess device experience, glucose parameters, and diabetes-related quality of life. Healthcare professionals will evaluate device experience and preference, including comparison with FreeStyle Libre 2.",[238,239,240,31,241],"Diabete Mellitus","Type2diabetes","type1diabetes","Pre Diabetes",[243,244,245,246,247,248,249],"CGM","Glucose monitoring","Time in range","estimated HbA1c","Time above range","Time below range","Diabetes Quality of life","2026-05-19",{"date":252,"type":37},"2026-05-26",{"date":254,"type":22},"2026-09-10",{"date":256,"type":22},"2027-08-10",{"name":258,"class":259},"Getz Pharma","INDUSTRY",{"id":261,"slug":262,"hasResults":12,"nctId":263,"briefTitle":264,"officialTitle":265,"acronym":266,"eligibilityCriteria":267,"healthyVolunteers":16,"sex":17,"minAge":54,"maxAge":55,"enrollmentInfo":268,"targetDuration":4,"studyType":235,"phases":4,"briefSummary":270,"conditions":271,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":274,"lastUpdatePostDateStruct":275,"startDateStruct":277,"completionDateStruct":279,"leadSponsor":281,"locationsCount":96},"100560003","growth-hormone-resistance-of-beta-cells-a-100560003","NCT06571487","Growth Hormone Resistance of Beta-cells A","Growth Hormone Resistance of Beta-cells in Women With Gestational Diabetes Mellitus","GHRB-A","Inclusion Criteria:\n\n* Singleton, full term pregnancy within the past 5 years\n* Body mass index ≥18.5 kg\u002Fm2 and \\\u003C45.0 kg\u002Fm2\n\nGroup specific inclusion criteria:\n\n* Gestational Diabetes Group: History of gestational diabetes in the most recent pregnancy\n* Control Group: no history of gestational diabetes\n\nExclusion Criteria:\n\n* Pregnant, planning to become pregnant during the study, or breastfeeding\n* Current diagnosis or history of type 1 or type 2 diabetes\n* Use of medications that can impact the study outcomes (e.g., GLP-1 receptor agonists)\n* History of bariatric surgery\n* Known, uncontrolled hypothyroidism\n* History of intracranial hypertension, including papilledema, or a condition that increases the risk of developing intracranial hypertension, such as Turner Syndrome, Prader-Willi Syndrome, or renal impairment\n* Current cancer or cancer that has been in remission less than 5 years\n* First degree relative with diabetes diagnosis\n* Evidence of significant anemia or significant end organ dysfunction (e.g., liver, kidney, heart disease)\n* Alcohol use disorder, use of controlled substances, or smoking \\>2 cigarettes per day\n* Greater than 3% weight loss within three months of screening or engaged in regular (≥3 days per week), continuous moderate- or high-intensity exercise of ≥30 min duration\n* Mentally disabled persons, prisoners, and persons with inability to grant voluntary informed consent",{"count":269,"type":22},30,"The purpose of the research study is to better understand how beta-cells (cells in the pancreas that make insulin and help regulate blood sugar) respond to growth hormone in people with a personal history of gestational diabetes (high blood sugar in pregnancy) at the University of Missouri. The aim of the study is to advance understanding of how growth hormone affects beta-cells and risk factors for developing gestational diabetes.",[31,272,273],"Obesity","Healthy","2026-05-05",{"date":276,"type":37},"2026-05-11",{"date":278,"type":37},"2025-10-22",{"date":280,"type":22},"2030-09-01",{"name":282,"class":44},"University of Missouri-Columbia",{"id":284,"slug":285,"hasResults":12,"nctId":286,"briefTitle":287,"officialTitle":288,"acronym":4,"eligibilityCriteria":289,"healthyVolunteers":16,"sex":17,"minAge":54,"maxAge":4,"enrollmentInfo":290,"targetDuration":4,"studyType":23,"phases":292,"briefSummary":293,"conditions":294,"keywords":296,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":299,"lastUpdatePostDateStruct":300,"startDateStruct":302,"completionDateStruct":304,"leadSponsor":306,"locationsCount":96},"100532177","community-health-worker-led-postpartum-diabetes-screening-100532177","NCT06209411","Community Health Worker-Led Postpartum Diabetes Screening","A Type 2 Hybrid Effectiveness-Implementation Trial of Community Health Workers to Improve Screening for Postpartum Diabetes in Urban Slums of India","Inclusion Criteria:\n\nPregnant Women:\n\n* Pregnant woman residing in one of pre-selected slum communities\n* 18 years or older\n* ≥ 24 weeks gestational age (as determined by self-reported last menstrual period or ultrasound)\n* Meet or exceed the threshold for GDM as determined by the CHW-delivered fasting OGTT\n* Agrees to study procedures, including in-person visits with the CHW postpartum if they are diagnosed with GDM\n\nCommunity Health Workers:\n\n* 18 years or older\n* Willingness to participate in study procedures and recruit eligible pregnant women\n* Agreement with goals of the study\n* Resides in one of the study communities\n* Willing to participate in surveys and interviews\n\nClinicians:\n\n* 18 years or older\n* Diabetes or obstetrics physicians\n* In a patient-facing position for over 1 year\n\nMinistry of Health Officials\n\n* 18 years or older\n* Employed by the Ministry of Health and Family Welfare, Maternal Health Division\n\nExclusion Criteria:\n\nPregnant Women:\n\n* Preexisting diabetes diagnosis prior to current pregnancy\n* Unable to tolerate food\u002F drink and remain fasting for 8 hoursUnwilling or unable to participate in study procedures\n* Unwilling or unable to provide informed consent\n\nCHW, Clinicians, Ministry of Health Officials\n\n1. Unwilling or unable to participate in study procedures\n2. Unwilling or unable to provide informed consent",{"count":291,"type":22},330,[25],"Women who experience gestational diabetes are at high risk of developing type 2 diabetes mellitus in the postpartum period-especially in low- and middle-income countries like India where the burden of diabetes is high and disproportionately affects women- but few receive the World Health Organization-recommended postpartum diabetes screening test. The investigators propose a cluster randomized clinical trial to determine whether community health worker-administered, home-based testing increases uptake of postpartum diabetes screening in the urban slums of Pune, India. The proposed study will provide an acceptable and scalable model that can be used to improve postpartum diabetes screening in other low-income settings, thereby improving early detection of diabetes in women and preventing morbidity and mortality in this high-risk population. A substudy will also test the effectiveness of a timed protein-fiber supplement in glucose control.",[295,31],"Diabetes Mellitus, Type 2",[297,298],"Community Health Workers","Type 2 Hybrid Effectiveness-Implementation Trial","2026-05-04",{"date":301,"type":37},"2026-05-06",{"date":303,"type":37},"2024-06-13",{"date":305,"type":22},"2027-10",{"name":307,"class":44},"Weill Medical College of Cornell University",{"id":309,"slug":310,"hasResults":12,"nctId":311,"briefTitle":312,"officialTitle":313,"acronym":314,"eligibilityCriteria":315,"healthyVolunteers":12,"sex":17,"minAge":54,"maxAge":55,"enrollmentInfo":316,"targetDuration":317,"studyType":235,"phases":4,"briefSummary":318,"conditions":319,"keywords":330,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":338,"lastUpdatePostDateStruct":339,"startDateStruct":340,"completionDateStruct":342,"leadSponsor":343,"locationsCount":96},"100636441","cardiometabolic-disease-and-substrate-metabolism-100636441","NCT07565727","Cardiometabolic Disease and Substrate Metabolism","Cardiometabolic Disease, Substrate Metabolism, and Abnormal Placental Pathology: a Multimodal Maternal-Fetal Study","CAP","Inclusion Criteria:\n\n* Age 18-45\n* Any pre-pregnancy BMI\n* At least one high risk OR one moderate risk factor for pre-eclampsia based on ACOG and USPSTF guidelines\n* Willingness to adhere to aspirin therapy\n* Willingness to undergo 2h OGTT for serum collection in addition to survey collection, indirect calorimetry, body composition measures, neonatal measures, etc.\n* Gestational age at enrollment \\\u003C18 weeks\n* Ability to speak, read, and communicate via English\n\nExclusion Criteria:\n\n* Type 2 Diabetes Mellitus\n* Type 1 Diabetes Mellitus\n* Current gestational diabetes mellitus\n* Current\u002Factive platelet disorder or bleeding diathesis (thrombocytopenia of any etiology, idiopathic thrombocytopenic purpura\u002FITP, thrombotic thrombocytopenic purpura\u002FTTP, von Willebrand disease, etc.)\n* Thrombophilia\n* Current use of NSAID for other indication (indomethacin, ibuprofen, etc.)\n* Current use of other immune-modulating agents and biologics (hydroxychloroquine, azathioprine, 6-mercaptopurine, IL-6 inhibitors, etc.)\n* Current or recent use of steroids\n* Current use of prophylactic or therapeutic anticoagulation\n* Medical contraindication to aspirin therapy\n* Molar pregnancy\n* Renal disease\n* Inability or unwillingness to give informed consent\n* Current psychiatric illness\u002Fsocial situation that would limit compliance with study requirements, as determined by the principal investigators",{"count":125,"type":22},"9 Months","This study's primary purpose is to determine the potential relationship between cardiometabolic disease, specifically insulin resistance (HOMA-IR), and maternal lipid oxidation.",[320,321,322,323,31,324,325,326,327,328,32,329],"Preeclampsia","Gestational Diabetes Mellitus (GDM)","Preeclampsia (PE)","Preeclampsia (PE) Risk","Gestational Diabetes Mellitus in Pregnancy","Cardiometabolic Diseases","Insulin Resistance","Placental Dysfunction","Pregnancy","Gestational Complications",[331,332,320,31,333,334,335,336,337],"Cardiometabolic disease","Substrate metabolism","Insulin resistance","HOMA-IR","Lipid oxidation","Placental dysfunction","Chorangiosis","2026-04-27",{"date":299,"type":37},{"date":341,"type":37},"2025-12-10",{"date":162,"type":22},{"name":344,"class":44},"University of Tennessee Graduate School of Medicine",{"id":346,"slug":347,"hasResults":12,"nctId":348,"briefTitle":349,"officialTitle":350,"acronym":4,"eligibilityCriteria":351,"healthyVolunteers":12,"sex":17,"minAge":54,"maxAge":352,"enrollmentInfo":353,"targetDuration":4,"studyType":23,"phases":355,"briefSummary":357,"conditions":358,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":359,"lastUpdatePostDateStruct":360,"startDateStruct":362,"completionDateStruct":364,"leadSponsor":365,"locationsCount":96},"100476350","phase-4-exenatide-pharmacokinetics-and-pharmacodynamics-in-gestational-diabetes-100476350","NCT05482789","Exenatide Pharmacokinetics and Pharmacodynamics in Gestational Diabetes","Pilot Study of Exenatide Pharmacokinetics and Pharmacodynamics in Gestational Diabetes","Inclusion Criteria:\n\n* Pregnant women (singleton)\n* Gestational diabetes not requiring medical therapy\n* Between 18 and 50 years of age\n* Able to give written informed consent\n\nExclusion Criteria:\n\n* Women in the first trimester of pregnancy\n* Hematocrit less than 30%\n* Current or past treatment with any hypoglycemic agent\n* Women with gastrointestinal disease or symptoms consistent with nausea, vomiting, abdominal pain or reflux requiring medical treatment.\n* Women with high triglyceride levels, history of gallbladder or pancreatic disease.\n* Clinical diagnosis or history of any renal insufficiency (or decreased creatinine clearance)","50 Years",{"count":354,"type":22},13,[356],"PHASE4","This study is being done to study how exenatide, an FDA-approved drug that lowers blood sugar in non-pregnant patients with type II diabetes, works in pregnant women. To do this, the investigators will study the drug's pharmacokinetics (what the body does to the drug; specifically, how quickly your body breaks down and excretes exenatide) and pharmacodynamics (what the drug does to the body; specifically, how effectively exenatide helps the participants' pancreas secrete insulin and how well it controls blood sugar after a meal). There are only two main drug therapies (insulin injections and glyburide pills) currently used for gestational diabetes and not all women achieve good enough blood sugar control without side effects. Therefore, the investigators hope to find out if exenatide might also be helpful in gestational diabetes.",[31],"2026-04-16",{"date":361,"type":37},"2026-04-20",{"date":363,"type":37},"2023-04-12",{"date":69,"type":22},{"name":366,"class":44},"Maisa N. Feghali, MD",{"id":368,"slug":369,"hasResults":12,"nctId":370,"briefTitle":371,"officialTitle":372,"acronym":373,"eligibilityCriteria":374,"healthyVolunteers":12,"sex":17,"minAge":54,"maxAge":352,"enrollmentInfo":375,"targetDuration":4,"studyType":23,"phases":377,"briefSummary":378,"conditions":379,"keywords":381,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":385,"lastUpdatePostDateStruct":386,"startDateStruct":387,"completionDateStruct":389,"leadSponsor":391,"locationsCount":392},"100606140","single-vs-multi-dose-insulin-for-glycemic-control-sugar-100606140","NCT07171684","Single vs Multi-Dose Insulin for Glycemic Control (SUGAR)","Single vs Multi-Dose Insulin for Glycemic Control (SUGAR): A Randomized Noninferiority Trial","SUGAR","Inclusion Criteria:\n\n* Diagnosed with type 2 diabetes mellitus or A2 gestational diabetes mellitus requiring insulin use during pregnancy\n* Aged between 18-50\n* Speak English or Spanish\n\nExclusion Criteria:\n\n* Pre-existing use of insulin\n* Gestational Age \\> or = 35w0d\n* Planning to follow-up with a doctor not associated with RWJ Barnabas or NYU Langone Health and\u002For deliver at a hospital other than RWJUH or NYU\n* Unwilling or unable to upload or email weekly blood sugar logs\n* Contraindication to Lispro or Lantus insulin, or patient chooses to not utilize insulin therapy\n* Fetal anomaly present",{"count":376,"type":22},176,[25],"The goal of this clinical trial is to see if diabetes in pregnancy can be treated with once daily dosing of insulin instead of once daily dosing plus insulin with meals. The main question this study aims to answer is:\n\n1. Can a once daily dose of long-acting insulin control blood sugars as well as long-acting insulin plus meal-time insulin?\n2. Do babies born to mothers who take one dose of long-acting insulin have more complications after birth than babies born to mothers who take long-acting and meal-time insulin? Researchers will compare one dose of long-acting insulin per day to this plus three doses of short-acting insulin with each meal to see if blood sugars are controlled.\n\nParticipants will send their blood sugar logs to the study staff weekly, instead of to their OB\u002FGYN, for adjustments to their insulin dosing.",[380,31],"Diabetes in Pregnancy",[382,383,153,87,181,384],"insulin glargine","insulin lispro","noninferiority","2026-04-13",{"date":359,"type":37},{"date":388,"type":37},"2025-11-26",{"date":390,"type":22},"2027-05-15",{"name":195,"class":44},2,{"id":394,"slug":395,"hasResults":12,"nctId":396,"briefTitle":397,"officialTitle":397,"acronym":398,"eligibilityCriteria":399,"healthyVolunteers":16,"sex":17,"minAge":54,"maxAge":352,"enrollmentInfo":400,"targetDuration":4,"studyType":235,"phases":4,"briefSummary":402,"conditions":403,"keywords":406,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":416,"lastUpdatePostDateStruct":417,"startDateStruct":418,"completionDateStruct":420,"leadSponsor":422,"locationsCount":96},"100587240","pregnancy-cohort-study-pregnancy-as-a-window-to-future-health-100587240","NCT06925815","Pregnancy Cohort Study: Pregnancy as a Window to Future Health","PregWin","Inclusion Criteria:\n\n* ongoing pregnancy prior to 14th gestational week, women with child wish; above 18 years of age, giving informed consent\n\nExclusion Criteria:\n\n* gestational age \\> 14th week of gestation; below 18 years of age; fetal genetic anomalies \u002Fmalformation",{"count":401,"type":22},800,"The goal of this observational cohort study is to gain deep insights into how metabolic disorders such as obesity or diabetes during pregnancy affect the metabolic and cardiovascular health of mother and child in the short and long term.\n\nIt will investigate the following questions:\n\n* How do maternal metabolic disorders affect pregnancy outcomes?\n* How do maternal metabolic disorders affect fetal growth?\n* How do maternal metabolic disorders affect the newborn's metabolism and body composition?\n* How do maternal metabolic disorders during pregnancy affect breast milk composition?\n* How do maternal metabolic disorders during pregnancy affect the metabolic health of the mother after birth? Participants in this study are pregnant women who will be asked to come to the clinics for three visits during their pregnancy, as well as for the delivery of their baby, and one time 2-3 months thereafter. At each visit, researchers will perform physical examinations (such as body composition measurements) and collect biological samples (blood, urine, saliva), clinical information, and lifestyle data. At birth, researchers will collect cord blood and breast milk as well as clinical data of the delivery and the health of the baby. Researchers will measure body fat in newborn babies and at 2-3 months of age.",[404,405,31],"Healthy Pregnant Women","Obese Pregnant Women",[181,407,408,409,410,411,412,413,414,153,415],"deep phenotyping","maternal metabolism","body composition","longitudinal pregnancy cohort study","fetal growth","obesity in pregnancy","neonatal adiposity","gestational weight gain","cardiovascular health","2026-04-09",{"date":385,"type":37},{"date":419,"type":37},"2023-07-27",{"date":421,"type":22},"2034-06",{"name":423,"class":44},"Medical University of Graz",{"id":425,"slug":426,"hasResults":12,"nctId":427,"briefTitle":428,"officialTitle":429,"acronym":430,"eligibilityCriteria":431,"healthyVolunteers":12,"sex":17,"minAge":54,"maxAge":4,"enrollmentInfo":432,"targetDuration":4,"studyType":235,"phases":4,"briefSummary":434,"conditions":435,"keywords":450,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":455,"lastUpdatePostDateStruct":456,"startDateStruct":457,"completionDateStruct":459,"leadSponsor":461,"locationsCount":463},"100613200","prior-study-pre-eclampsia-risk-in-oocyte-recipients-100613200","NCT07263490","PRIOR Study (Pre-eclampsia Risk In Oocyte Recipients)","PRIOR Study (Pre-eclampsia Risk In Oocyte Recipients) - Investigating Matching, Biomarkers and Outcomes.","PRIOR","Inclusion Criteria:\n\n* Age \\> 18 years\n* BMI \\\u003C 35 kg\u002Fm2\n* Normal wet smear within the past three years\n* Both nulli- and multiparous\n* Singletons and multiple gestations\n\nExclusion Criteria:\n\n* Age \\\u003C 18 years\n* BMI \\> 35 kg\u002Fm2\n* HIV\u002F hepatitis\n* Essential hypertension\n* Chronic kidney disease\n* Undiagnosed vaginal bleeding\n* Uterine malformations\n* Persisting ovarian cysts\n* Tumors in hypothalamus, pituitary, thyroid, or adrenal glands.\n* Previous breast cancer\n* Known BRCA 1 or 2 gene\n* Unregulated thyroid disease\n* Cardiovascular disease\n* Breast feeding\n* Present or previous chemotherapy\u002Fradiation therapy\n* Present or previous malignant disease\n* Smoking\n* Alcohol\u002Fdrug abuse",{"count":433,"type":22},462,"The aim of this prospective observational cohort study is to investigate the pathophysiological mechanisms behind and risk of pre-eclampsia in women pregnant after fertility treatment with oocyte donation. The participants are included in of of two cohorts. One includes women pregnant after oocyte donation whereas the other includes women pregnant after IVF treatment with autologous oocytes.\n\nParticipants will be followed throughout pregnancy with blood samples, blood pressure, clinical controls and ultrasound examinations. Clinical outcomes will be registered post-partum.",[436,437,438,439,440,441,442,443,444,445,31,446,447,448,449],"Pre-eclampsia","Oocyte Donation","Pre-Eclampsia; Complicating Pregnancy","Pre-Eclampsia; Mild","Pre-Eclampsia, Severe","Pre-eclampsia or Eclampsia With Pre-existing Hypertension","ART","Neonatal Morbidity","Neonatal Mortality","Placental Abruption","Preterm Labor","Post-partum Hemorrhage (PPH)","Intrauterine Growth Restriction (IUGR)","Hypertensive Disorders of Pregnancy",[436,320,442,451,452,453,454],"Gestational hypertension","Oocyte donation","Egg donation","Gamete donation","2026-04-07",{"date":385,"type":37},{"date":458,"type":37},"2024-10-21",{"date":460,"type":22},"2028-06-01",{"name":462,"class":44},"Copenhagen University Hospital, Hvidovre",6,{"id":465,"slug":466,"hasResults":12,"nctId":467,"briefTitle":468,"officialTitle":469,"acronym":470,"eligibilityCriteria":471,"healthyVolunteers":16,"sex":17,"minAge":54,"maxAge":352,"enrollmentInfo":472,"targetDuration":4,"studyType":235,"phases":4,"briefSummary":474,"conditions":475,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":477,"lastUpdatePostDateStruct":478,"startDateStruct":480,"completionDateStruct":482,"leadSponsor":484,"locationsCount":96},"100530253","early-investigation-of-glucose-monitoring-after-gestational-diabetes-pilot-100530253","NCT06184373","Early Investigation of Glucose Monitoring After Gestational Diabetes Pilot","Early Investigation of Glucose Monitoring After Gestational Diabetes (ENGAGED): Utility and Acceptability of Continuous Glucose Monitoring in the Early Postpartum Period After Gestational Diabetes Mellitus","ENGAGED","Inclusion Criteria:\n\n* Women with a viable singleton intrauterine pregnancy\n* Able to understand the study, and having understood, provide written informed consent in English\n* Recent pregnancy affected by gestational diabetes\n\nExclusion Criteria:\n\n* Pregestational Diabetes (Type I or Type II)\n* Continued use of diabetes medications (including metformin and insulin) immediately after delivery\n* Preterm delivery (\\\u003C 37 weeks gestation)\n* Twin or higher order gestation\n* No access to a smartphone\n* Unable or unwilling to wear CGM or return for follow up at postpartum mother-infant dyad clinic\n* Participation in this trial in a prior pregnancy\n* History of skin allergy to adhesive products or CGM",{"count":473,"type":22},20,"One third of women with gestational diabetes (GDM), diabetes diagnosed during pregnancy, have abnormal glucose levels within 3 years after pregnancy, but follow up is low. Continuous glucose monitors (CGM), a small sensor inserted under the skin, may be able to screen women with GDM for diabetes risk. The investigators will ask postpartum women to use CGM at 6-8 weeks postpartum and answer surveys about quality of life after wearing the CGM. The investigators will collect data on blood glucose trends for future studies if participants find CGM use acceptable. The investigators hope to learn if CGM could improve postpartum follow up experiences for people with recent GDM.",[31,476],"Hyperglycemia","2026-01-20",{"date":479,"type":37},"2026-01-22",{"date":481,"type":37},"2025-06-06",{"date":483,"type":22},"2027-05-30",{"name":485,"class":44},"Ohio State University",{"id":487,"slug":488,"hasResults":12,"nctId":489,"briefTitle":490,"officialTitle":491,"acronym":492,"eligibilityCriteria":493,"healthyVolunteers":12,"sex":17,"minAge":54,"maxAge":55,"enrollmentInfo":494,"targetDuration":4,"studyType":23,"phases":496,"briefSummary":498,"conditions":499,"keywords":500,"overallStatus":108,"whyStopped":4,"lastUpdateSubmitDate":504,"lastUpdatePostDateStruct":505,"startDateStruct":507,"completionDateStruct":509,"leadSponsor":510,"locationsCount":4},"100621335","phase-2-melatonin-for-glycemic-control-in-gestational-diabetes-mellitus-100621335","NCT07369284","Melatonin for Glycemic Control in Gestational Diabetes Mellitus","Efficacy of Melatonin in Addition to Standard Care in Glycemic Control of Patients With Gestational Diabetes Mellitus: a Randomized, Double-blind, Placebo-controlled Trial","MELODY","Inclusion Criteria:\n\n* Women aged 18 to 45 years\n* Singleton pregnancy\n* A diagnosis of GDM from a 75-g OGTT during 24 to 28 gestational weeks, according to the IADPSG criteria, with at least fasting plasma glucose (FPG) ≥ 5.1 mmol\u002FL\n* Intending to receive obstetric care and deliver in the study center\n* Willing and able to provide written informed consent and follow the study procedure\n\nExclusion Criteria:\n\n* Use of melatonin 1 month before pregnancy or\u002Fand during pregnancy\n* Night shift work or exposed to jetlag on a regular basis during pregnancy\n* Contraindications to melatonin use, including hypersensitive or allergic to melatonin\n* Use of antidepressive or antipsychotic medications which can interfere with melatonin metabolism and\u002For elimination, such as fluvoxamine, 5- or 8-methoxypsoralen, cimetidine, quinolones, and other CYP1A2 inhibitors; carbamazepine, rifampicin, and other CYP1A2 inducers; and zaleplon, zolpidem, zopiclone, and other non-benzodiazepine hypnotics\n* Pre-pregnancy diabetes, including patients diagnosed with diabetes before conception, fasting plasma glucose ≥ 7.0 mmol\u002FL or HbA1c ≥ 6.5% in the first trimester, typical hyperglycemic symptoms or hyperglycemic crisis with random blood glucose ≥ 11.1 mmol\u002FL\n* Other major diseases before gestation, e.g. hypertensive disorders, rheumatology or malignant diseases, infected with hepatitis B or hepatitis C, chronic diseases leading to impaired heart, liver, or renal function\n* Major fetal anomalies",{"count":495,"type":22},150,[497],"PHASE2","The goal of this randomized, double-blind, placebo-controlled clinical trial is to evaluate whether melatonin supplementation improves glycemic control in pregnant women diagnosed with gestational diabetes mellitus (GDM).\n\nThe main question it aims to answer is:\n\nDoes melatonin supplementation help with glycemic control, especially in lowering fasting plasma glucose level?\n\nResearchers will compare melatonin to a placebo (a look-alike substance that contains no melatonin) to see if melatonin works to improve glycemic control.\n\nParticipants will:\n\n1. Take melatonin or a placebo every day after randomization until delivery\n2. Visit the antenatal clinic once every 1 to 2 weeks for follow-ups",[31],[501,502,503],"Gestational diabetes","Melatonin","Fasting plasma glucose","2026-01-17",{"date":506,"type":37},"2026-01-27",{"date":508,"type":22},"2026-02",{"date":162,"type":22},{"name":511,"class":44},"Obstetrics & Gynecology Hospital of Fudan University",{"id":513,"slug":514,"hasResults":12,"nctId":515,"briefTitle":516,"officialTitle":516,"acronym":517,"eligibilityCriteria":518,"healthyVolunteers":12,"sex":17,"minAge":54,"maxAge":4,"enrollmentInfo":519,"targetDuration":4,"studyType":235,"phases":4,"briefSummary":520,"conditions":521,"keywords":523,"overallStatus":108,"whyStopped":4,"lastUpdateSubmitDate":526,"lastUpdatePostDateStruct":527,"startDateStruct":529,"completionDateStruct":531,"leadSponsor":533,"locationsCount":535},"100620389","stelo-real-time-continuous-glucose-monitor-use-postpartum-for-lifelong-optimal-wellness-100620389","NCT07356986","Stelo Real-time Continuous Glucose Monitor Use Postpartum for Lifelong Optimal Wellness","STELO-GLOW","Inclusion Criteria:\n\n* Gestational Diabetes Mellitus (GDM) diagnosis by 1- or 2-step Oral Glucose Tolerance Test (OGTT) during pregnancy or \\>= 200 mg following any glucose challenge (50g, 75g, 100g)\n* Has a smart phone compatible to support Dexcom Stelo app\n* Able to read, write, and understand English\n* Meet Stelo Glucose Biosensor Indications for Use (IFU) per approved commercial labeling\n* Willing to follow all study procedures\n\nExclusion Criteria:\n\n* Greater than 6 weeks and 6 days postpartum at enrollment\n* Preexisting Type 1 Diabetes (T1D) or Type 2 Diabetes (T2D)\n* End-stage renal failure (on dialysis)\n* Heart failure\n* Other uncontrolled high-risk condition as determined exclusionary by site investigators\n* Extensive skin changes\u002Fdiseases that preclude wearing the required system on normal skin (e.g. extensive psoriasis, recent burns or severe sunburn, extensive eczema, extensive scarring, extensive tattoos, dermatitis herpetiformis) at the proposed wear sites\n* Known severe allergy to medical-grade adhesives\n* Any condition that, in the opinion of the investigator, would interfere with their participation in the trial\n* Obesity surgery\n* Insulin use prior to discharge home from the delivery admission\n* Current participation in another postpartum Continuous Glucose Monitoring (CGM) or lifestyle intervention trial",{"count":125,"type":22},"The purpose of this prospective observational study is to gather exploratory and practical use data of the Dexcom Stelo Glucose Biosensing System (Stelo), an over-the-counter (OTC) real-time Continuous Glucose Monitoring (CGM) system among patients with Gestational Diabetes Mellitus (GDM) in their most recent pregnancy.",[31,522],"Postpartum",[524,525],"Continuous Glucose Monitoring","Postpartum Glucose Management","2026-01-12",{"date":528,"type":37},"2026-01-21",{"date":530,"type":22},"2026-01",{"date":532,"type":22},"2027-12",{"name":534,"class":44},"Oregon Health and Science University",3,{"id":537,"slug":538,"hasResults":12,"nctId":539,"briefTitle":540,"officialTitle":541,"acronym":4,"eligibilityCriteria":542,"healthyVolunteers":12,"sex":231,"minAge":54,"maxAge":55,"enrollmentInfo":543,"targetDuration":4,"studyType":23,"phases":545,"briefSummary":546,"conditions":547,"keywords":548,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":553,"lastUpdatePostDateStruct":554,"startDateStruct":556,"completionDateStruct":558,"leadSponsor":560,"locationsCount":392},"100618845","effect-of-conventional-vs-intensive-management-on-gestational-diabetes-and-maternal-fetal-outcomes-100618845","NCT07336914","Effect of Conventional vs Intensive Management on Gestational Diabetes and Maternal Fetal Outcomes","Effect of Conventional vs Intensive Management on Gestational Diabetes and Maternal Fetal Outcomes: Randomized Controlled Trial.","Inclusion Criteria:\n\n* Maternal age between 18-45 years\n* Gestational age at enrollment 24 - 28 weeks\n* Patients having Hba1c levels less then 6%\n\nExclusion Criteria:\n\n* Patients having twin pregnancies\n* Patients having PCOS\n* Diabetes diagnosed prior to pregnancy\n* Patients having severe hypertension\n* Patients having renal diseases\n* Patients using glucose altering medications",{"count":544,"type":22},60,[25],"This study involved two management protocols to manage diabetes in pregnancy. Sixty patients having GDM will be recruited on the basis of the OGTT and randomly allocated to two management groups. One group of patients will receive counselling and the conventional method of management. while the other group will receive a tailored diet plan and physical activity with low caloric and moderate intense exercises. Both groups will receive a dietary plan based on their sugar levels weekly basis and physical activity with pharmacotherapy to adjust their sugar levels, while the intensive group will have rigorous monitoring on a monthly basis and frequent visits with repeated lab checks. This will help us to reduce short and long-term complications with improved maternal and neonatal outcomes.",[31],[321,549,550,551,552],"Intensive Management","Randomized Controlled Trial (RCT)","Glycemic Control","Maternal Health","2026-01-01",{"date":555,"type":37},"2026-01-13",{"date":557,"type":37},"2025-10-01",{"date":559,"type":22},"2026-04-25",{"name":561,"class":44},"Khyber Medical University Peshawar",{"id":563,"slug":564,"hasResults":12,"nctId":565,"briefTitle":566,"officialTitle":567,"acronym":4,"eligibilityCriteria":568,"healthyVolunteers":12,"sex":17,"minAge":54,"maxAge":4,"enrollmentInfo":569,"targetDuration":4,"studyType":235,"phases":4,"briefSummary":571,"conditions":572,"keywords":573,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":583,"lastUpdatePostDateStruct":584,"startDateStruct":586,"completionDateStruct":588,"leadSponsor":590,"locationsCount":96},"100617155","maternal-sleep-and-lifestyle-metabolic-health-and-perinatal-outcomes-in-gestational-diabetes-100617155","NCT07314944","Maternal Sleep and Lifestyle, Metabolic Health, and Perinatal Outcomes in Gestational Diabetes","Integrated Assessment of Sleep, Mental Health, Lifestyle Behaviors, Metabolic Markers, and Perinatal Outcomes in Women With Gestational Diabetes Mellitus: A Prospective Cohort Study","Inclusion Criteria:\n\n* Pregnant women aged 18 years or older\n* New diagnosis of gestational diabetes mellitus (GDM) according to IADPSG criteria\n* Gestational age 24-34 weeks at enrollment\n* Able to complete study questionnaires (sleep, anxiety, eating behavior, lifestyle)\n* Able to provide informed consent\n* For participants in the home-monitoring pathway: ability to use a smartphone and the FreeStyle Libre device\n\nExclusion Criteria:\n\n* Pre-existing type 1 or type 2 diabetes mellitus\n* Current preeclampsia or major obstetric complications at enrollment\n* Major psychiatric disorders interfering with participation\n* Chronic use of sedatives or anxiolytic medications\n* Inability to complete questionnaires\n* Planned delivery outside the study's hospital network\n* Any condition judged by clinicians to interfere with participation or data reliability",{"count":570,"type":22},100,"The goal of this observational study is to learn how sleep quality, mental health, lifestyle behaviors, and metabolic markers are related to glucose control and pregnancy outcomes in women with gestational diabetes mellitus (GDM). The main questions it aims to answer are:\n\n* Do differences in sleep quality, anxiety levels, and eating behaviors relate to differences in glycemic control in women with GDM?\n* Are maternal metabolic markers (such as glucose, liver enzymes, and lipid levels) associated with perinatal outcomes such as birth weight, cesarean delivery, and neonatal complications?\n* To compare women who undergo short inpatient glucose monitoring with women who undergo home-based digital glucose monitoring to see if the mode of monitoring is related to differences in sleep, mental health, metabolic profiles, or perinatal outcomes.\n\nParticipants will:\n\n* Complete questionnaires on sleep, anxiety, lifestyle, and eating behaviors\n* Undergo routine laboratory testing, including metabolic and blood markers.\n* Have glucose monitored either during a short hospital stay or through home use of the FreeStyle Libre sensor.\n* Be followed from GDM diagnosis (24-34 weeks) until delivery to assess maternal and newborn outcomes",[31],[574,575,576,577,578,579,580,581,551,582],"Gestational Diabetes Mellitus","Sleep Quality","Anxiety","Mental Health","Eating Behavior","Lifestyle Factors","Physical Activity","Metabolic Markers","Perinatal Outcomes","2025-12-30",{"date":585,"type":37},"2026-01-02",{"date":587,"type":37},"2025-11-01",{"date":589,"type":22},"2030-01-01",{"name":591,"class":44},"University of Split, School of Medicine",{"id":593,"slug":594,"hasResults":12,"nctId":595,"briefTitle":596,"officialTitle":596,"acronym":4,"eligibilityCriteria":597,"healthyVolunteers":16,"sex":17,"minAge":54,"maxAge":352,"enrollmentInfo":598,"targetDuration":4,"studyType":235,"phases":4,"briefSummary":600,"conditions":601,"keywords":602,"overallStatus":108,"whyStopped":4,"lastUpdateSubmitDate":606,"lastUpdatePostDateStruct":607,"startDateStruct":609,"completionDateStruct":610,"leadSponsor":612,"locationsCount":4},"100614234","individualized-early-diagnosis-and-treatment-system-of-gestational-diabetes-mellitus-gdm-based-on-new-continuous-glucose-monitoring-cgm-technology-100614234","NCT07276945","Individualized Early Diagnosis and Treatment System of Gestational Diabetes Mellitus (GDM) Based on New Continuous Glucose Monitoring (CGM) Technology","Inclusion Criteria:\n\n* ① Early pregnancy (≤14 weeks) pregnant women;\n* ② Singleton pregnancies;\n* ③ Early pregnancy psychological scores (PHQ-9 and GAD-7) \\\u003C10 points;\n* ④ Consent to participate in the study and sign an informed consent form.\n\nExclusion Criteria:\n\n* ① Twin or multiple pregnancies;\n* ② Diabetes mellitus complicated with pregnancy;\n* ③ Severe pregnancy complications;\n* ④ Pre-existing significant cardiovascular, hepatic, renal, hematologic, or autoimmune diseases;\n* ⑤ History of smoking, alcohol abuse, or narcotic and drug use;\n* ⑥ Early pregnancy psychological assessment (PHQ-9 or GAD-7) score ≥10.",{"count":599,"type":22},300,"Gestational diabetes mellitus (GDM), as the most common metabolic complication of pregnancy, poses a serious threat to maternal and fetal metabolic health. However, current GDM diagnosis faces several problems such as static, single-point, cumbersome to operate and delayed diagnosis, highlighting an urgent need to establish an individualized system for early prediction, diagnosis, and intervention.\n\nThis project aims to develop a mother-child cohort covering pregnancy and the perinatal period to propose early diagnostic criteria for GDM based on continuous glucose monitoring (CGM) technology, as well as developing clinically applicable AI-based tools for analyzing and interpreting CGM data, along with strategies to assist in GDM diagnosis. Furthermore, it will investigate CGM parameters and multi-omics biomarkers suitable for predicting maternal and fetal outcomes, culminating in the creation of an intelligent management platform for GDM. This project is expected to enhance the early identification rate of gestational diabetes, potentially advancing the diagnostic and therapeutic window for the condition, thereby improving both short- and long-term maternal and fetal health outcomes.",[31],[603,154,604,605],"gestational diabetes mellitus","early diagnosis","mother-child outcomes","2025-12-20",{"date":608,"type":37},"2025-12-29",{"date":341,"type":22},{"date":611,"type":22},"2028-07-01",{"name":613,"class":44},"Peking Union Medical College Hospital",{"id":615,"slug":616,"hasResults":12,"nctId":617,"briefTitle":618,"officialTitle":619,"acronym":620,"eligibilityCriteria":621,"healthyVolunteers":16,"sex":17,"minAge":54,"maxAge":4,"enrollmentInfo":622,"targetDuration":4,"studyType":23,"phases":624,"briefSummary":625,"conditions":626,"keywords":630,"overallStatus":108,"whyStopped":4,"lastUpdateSubmitDate":635,"lastUpdatePostDateStruct":636,"startDateStruct":637,"completionDateStruct":638,"leadSponsor":639,"locationsCount":96},"100617121","prenatal-exercise-including-perineal-massage-and-maternal-neonatal-outcomes-100617121","NCT07314502","Prenatal Exercise Including Perineal Massage and Maternal-Neonatal Outcomes","Prenatal Exercise Including Perineal Massage and Maternal-Neonatal Outcomes: A Randomized Controlled Trial","PEPM-RCT","Inclusion Criteria:\n\n* Age ≥ 18 years；\n* Gestational age between 8 and 16 weeks\n* No contraindications to exercise；\n* Able to attend in-person exercise classes；\n* Having obtained hospital approval to participate in this exercise program；\n* Able to carry out basic communication in Mandarin Chinese;\n* Planning to deliver at the same maternal and child health hospital.\n\nExclusion Criteria:\n\n* Unable to deliver at the same hospital due to personal reasons；\n* Currently participating in other research projects；\n* Presence of absolute contraindications to exercise；\n* Uncertain about being able to attend three in-person exercise sessions per week；\n* Unable to communicate in Mandarin Chinese.",{"count":623,"type":22},2000,[25],"The study is divided into three phases:\n\nPhase 1: Baseline survey to obtain an overall understanding of the current situation of voluntary participation in prenatal perineal massage.\n\nPhase 2: Follow-up survey to further assess the current situation of voluntary prenatal exercise and prenatal perineal massage.\n\nPhase 3: Implementation of an intervention combining prenatal exercise and perineal massage.\n\nThe goal of this clinical trial is to learn whether a combined prenatal program of supervised, moderate-intensity exercise plus professionally administered antenatal perineal massage can improve maternal and newborn outcomes and can be safely implemented as part of routine antenatal care in healthy pregnant women receiving care at participating hospitals.\n\nThe main questions it aims to answer are:\n\n1. Does the combined prenatal program reduce urinary incontinence during pregnancy and after delivery?\n2. Does the combined prenatal program reduce depressive symptoms during pregnancy and in the postpartum period?\n3. Does the combined prenatal program lower the risk of gestational diabetes mellitus?\n4. Does the combined prenatal program reduce neonatal complications, including macrosomia?\n5. Do spontaneous, self-initiated prenatal exercise and structured, supervised prenatal exercise differ in their effects on maternal and neonatal outcomes ()?\n\nResearchers will compare the combined prenatal program to usual antenatal care to determine whether the intervention improves maternal and neonatal outcomes and is safe, feasible, and acceptable in a real-world clinical setting.\n\nParticipants will:\n\n1. Be screened and enrolled during pregnancy and complete baseline and follow-up assessments during pregnancy and after delivery.\n2. Be randomly assigned to either an intervention group or a usual-care control group.\n3. If assigned to the intervention group, attend supervised moderate-intensity exercise sessions three times per week (approximately 60 minutes per session) throughout pregnancy and receive antenatal perineal massage delivered by trained health professionals during late pregnancy.\n4. Provide questionnaire-based information and clinical data collected during routine visits and from medical records for outcome evaluation.",[627,628,629,31],"Postpartum Urinary Incontinence","Postpartum Depression (PPD)","Neonatal Complications",[631,632,633,634,328],"Exercise","Urinary Incontinence","Postpartum Depression","Macrosomia","2025-12-17",{"date":585,"type":37},{"date":553,"type":22},{"date":41,"type":22},{"name":640,"class":44},"South China Normal University",{"id":642,"slug":643,"hasResults":12,"nctId":644,"briefTitle":645,"officialTitle":646,"acronym":4,"eligibilityCriteria":647,"healthyVolunteers":16,"sex":17,"minAge":648,"maxAge":4,"enrollmentInfo":649,"targetDuration":4,"studyType":23,"phases":650,"briefSummary":651,"conditions":652,"keywords":653,"overallStatus":108,"whyStopped":4,"lastUpdateSubmitDate":341,"lastUpdatePostDateStruct":656,"startDateStruct":658,"completionDateStruct":660,"leadSponsor":662,"locationsCount":96},"100550299","lifestyle-interventions-to-improve-glycemic-parameters-and-reduce-gestational-diabetes-in-high-risk-pregnant-individuals-100550299","NCT06445270","Lifestyle Interventions to Improve Glycemic Parameters and Reduce Gestational Diabetes in High-risk Pregnant Individuals","Evidence-informed Lifestyle Interventions to Improve Glycemic Parameters and Reduce Gestational Diabetes in High-risk Pregnant Individuals","Inclusion Criteria:\n\n* Gestational age less or equal to 16 + 6 weeks confirmed via ACOG dating guidelines AND one of the following\n* 35 years of age or older\n* Family history of first degree relative with diabetes mellitus\n* Body Mass Index (BMI) greater than or equal to 30\n* Hemoglobin A1c value between 5.9% to 6.4%\n\nExclusion Criteria:\n\n* Multiple gestations\n* Current diagnosis of Type 1 or 2 diabetes mellitus including a diagnosis during this pregnancy\n* Pre-pregnancy chronic (\\>2 weeks) usage of systemic steroids (inhaled and short term usage acceptable)\n* Planned pregnancy termination\n* Currently taking or took 3 months prior to conception Metformin\n* Unable to provide informed consent in English or Spanish\n* Major fetal anomalies listed below that are known prior to enrollment.\n\nMajor fetal anomalies:\n\n* Congenital diaphragmatic hernia\n* Congenital cystic adenomatoid malformation\n* Pleural effustions\n* Chylothorax\n* Bronchogenic cyst\n* Bronchopulmonary sequestration\n* Anomalous pulmonary venous return\n* Tricuspid atresia\n* Mitral atresia\n* Double right ventricle\n* Ebstein's malformation\n* Pulmonary atresia\n* Hypoplastic left heart syndrome\n* Aortic coarctation\n* Fetal arrhythmias\n* Transposition of the great vessels\n* Tetrology of Fallot\n* Double outlet right ventricle\n* Aortic stenosis\n* Holoprosencephaly\n* Anencephaly\n* Dandy-Walker malformation or variant\n* Septo-optic dysplasia\n* Neural tube defect\n* Vein of Galen aneurysm\n* Bilateral renal agenesis\n* Cystic renal disease\n* Obstructive uropathy\n* Horseshoe kidney\n* Megacystis microcolon\n* Cloacal abnormality\n* Achondrogenesis\n* Thanatophoric dysplasia\n* Thoracic dysplasia\n* Osteogenesis imperfecta\n* Short rib polydacyly\n* Any skeletal defect with suspected small thorax\n* Hypophosphatemia\n* Any karyotypic abnormality\n* Any suspected genetic syndrome\n* Cleft lip\u002Fpalate\n* Micrognathia\n* Hydrops\n* Fetal anemia (\\\u003C35% on cordocentesis)\n* Neck mass\n* Gastroschsis\n* Omphalocele","14 Years",{"count":570,"type":22},[25],"The goal of this study is assess the impact of a higher intensity dietary and activity counseling program to improve blood sugar control and reduce the chance of developing gestational diabetes (GDM) as compared to the current standard diet and activity counseling.",[31,32],[153,654,181,655],"prevention","continuous glucose monitor",{"date":657,"type":37},"2025-12-18",{"date":659,"type":22},"2026-08",{"date":661,"type":22},"2031-12",{"name":71,"class":44},{"id":664,"slug":665,"hasResults":12,"nctId":666,"briefTitle":667,"officialTitle":667,"acronym":4,"eligibilityCriteria":668,"healthyVolunteers":16,"sex":17,"minAge":54,"maxAge":352,"enrollmentInfo":669,"targetDuration":4,"studyType":23,"phases":671,"briefSummary":673,"conditions":674,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":677,"lastUpdatePostDateStruct":678,"startDateStruct":680,"completionDateStruct":682,"leadSponsor":684,"locationsCount":96},"100558169","early-phase-1-role-of-et-1-physical-activity-and-sedentary-behavior-in-microvascular-dysfunction-following-gdm-100558169","NCT06547619","Role of ET-1, Physical Activity, and Sedentary Behavior in Microvascular Dysfunction Following GDM","INCLUSION CRITERIA\n\n* history of pregnancy within 5 years of the study visit\n* had healthy pregnancy OR had gestational diabetes diagnosed by their obstetrician and confirmed according to the American College of Obstetricians and Gynecologists criteria for gestational diabetes.\n\nEXCLUSION CRITERIA\n\n* skin diseases,\n* current tobacco or electronic cigarette\u002Fvape pen use,\n* diagnosed or suspected hepatic or metabolic disease including diabetes,\n* statin or other cholesterol-lowering medication,\n* current antihypertensive medication,\n* history of preeclampsia or gestational hypertension\n* current hypertension,\n* current pregnancy,\n* body mass index \\\u003C18.5 kg\u002Fm2,\n* allergy to materials used during the experiment.(e.g. latex), known allergies to study drugs.",{"count":670,"type":22},40,[672],"EARLY_PHASE1","Women with a history of gestational diabetes mellitus (GDM) are at a 2-fold greater risk for the development of overt cardiovascular disease (CVD) following the effected pregnancy. While subsequent development of type II diabetes elevates this risk, prior GDM is an independent risk factor for CVD morbidity, particularly, within the first decade postpartum. GDM is associated with impaired endothelial function during pregnancy and decrements in macro- and microvascular function persist postpartum, despite the remission of insulin resistance following delivery. Collectively, while the association between GDM and elevated lifetime CVD risk is clear, and available evidence demonstrates a link between GDM and vascular dysfunction in the decade following pregnancy, the mechanisms mediating this persistent dysfunction remain unexamined.\n\nThe purpose of this investigation is to examine the role of endothelin-1, a potent vasoconstrictor, in aberrant microvascular function in otherwise healthy women with a history of GDM and to identify whether this mechanism is influenced by physical activity and sedentary behavior.",[31,675,676],"Endothelial Dysfunction","Physical Inactivity","2025-12-08",{"date":679,"type":37},"2025-12-09",{"date":681,"type":37},"2024-10-01",{"date":683,"type":22},"2027-05",{"name":685,"class":44},"Anna Stanhewicz, PhD"]